SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?
Description
NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.
Files
9169-9171.pdf
Files
(289.1 kB)
Name | Size | Download all |
---|---|---|
md5:573344a84833926b03f55b2bd71c3fd8
|
289.1 kB | Preview Download |
Additional details
Related works
- Is identical to
- 10.26355/eurrev_202009_22867 (DOI)